| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 09/27/2005 | US6949580 Anticancer agents; restenosis; antiinflammatory agents; cardiovascular disorders |
| 09/27/2005 | US6949579 Central nervous system disorders; antidiabetic agents |
| 09/27/2005 | US6949565 Protein kinase inhibitors |
| 09/27/2005 | US6949561 polycyclic compound comprises sulphamate group attached to one of the ring components, wherein ring is naphtho(2,1-f)quinoline |
| 09/27/2005 | US6949547 Antidiabetic agents; central nervous system disorders; cardiovascular disorders; hypotensive agents; anticancer agents |
| 09/27/2005 | US6949546 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity |
| 09/27/2005 | US6949544 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 09/27/2005 | US6949541 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof |
| 09/27/2005 | US6949540 Substituted pyrazoles |
| 09/27/2005 | US6949538 Compounds, compositions, and methods |
| 09/27/2005 | US6949535 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one |
| 09/27/2005 | US6949515 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases |
| 09/27/2005 | US6949510 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/27/2005 | US6949356 Methods for improving secondary metabolite production in fungi |
| 09/27/2005 | US6949257 Substance P antagonist; antidepressants; central nervous system disorders; respiratory system disorders |
| 09/27/2005 | US6949244 produced by hybridoma cell line ATCC No. HB 12020; elicits an immune response against (human milk fat globule) HMFG in non-human primates |
| 09/27/2005 | CA2428206C Methods for the treatment of cellular proliferative disorders |
| 09/27/2005 | CA2120942C Nitric esters of derivatives of the 2-(2,6-di-halo-phenylamino)phenyl-acetic acid and process for their preparation |
| 09/26/2005 | WO2005110452A2 MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS |
| 09/26/2005 | CA2847331A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders |
| 09/26/2005 | CA2847142A1 Multiple-variable dose regimen for treating tnf.alpha.-related disorders |
| 09/26/2005 | CA2504868A1 Multiple-variable dose regimen for treating tnf.alpha. related disorders |
| 09/22/2005 | WO2005087775A1 Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient |
| 09/22/2005 | WO2005087243A1 Active ingredient complex of seaweed plants, especially the zosteraceae family, method for the production thereof, and use of the same |
| 09/22/2005 | WO2005087182A1 Functional powders |
| 09/22/2005 | WO2003099270A8 Methods of treating allergic reactions |
| 09/22/2005 | US20050209341 R-(-)-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane or its hydrochloride salt; inhibiting the uptake of norepinephrine and serotonin; antidepressants, analgesics; treating sleep disorders, autism, psychological disorders, eating disorders |
| 09/22/2005 | US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/22/2005 | US20050209325 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators |
| 09/22/2005 | US20050209286 RXR activating molecules |
| 09/22/2005 | US20050209279 Process for production of piperidine derivatives |
| 09/22/2005 | US20050209268 Administering optionally hydrogenated 2-alkyl-1-(alkylsulfonylalkyl)imidazo[4,5-c]quinoline-4-amines to induce biosynthesis of cytokines such as IFN-alpha and/or TNF-alpha; treating viral diseases and neoplastic diseases |
| 09/22/2005 | US20050209267 Thioether substituted imidazoquinolines |
| 09/22/2005 | US20050209253 Corticotropin releasing factor (CRF) receptor antagonists; nervous system disorders, ischemia, gastrointestinal disorders, hypertension, eating disorders, sleep disorders; e.g. 2-(1-[7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidin-2-yl)-ethanol |
| 09/22/2005 | US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/22/2005 | US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/22/2005 | US20050209230 2,4-Pyrimidinediamine compounds and their uses |
| 09/22/2005 | US20050209224 N4-(4H-5-pyrid[1,4]oxazin-6-yl)-2,4-pyrimidinediamine derivatives; for treating rheumatoid arthritis |
| 09/22/2005 | US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline |
| 09/22/2005 | US20050209206 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier |
| 09/22/2005 | US20050209192 Autoimmune disorders; modulating protein kinase C activity |
| 09/22/2005 | US20050209161 Drugs for treatment of inflammation/blood brain barrier degradation;administering to a subject in need of such treatment, a pharmaceutically effective amount of a peptide antagonist of zonulin, wherein the peptide antagonist binds to a zonula occludens toxin receptor |
| 09/22/2005 | US20050209159 Effectors of dipeptidyl peptidase IV for topical use |
| 09/22/2005 | US20050208625 Monoclonal antibodies with reduced immunogenicity |
| 09/22/2005 | US20050208619 29 human secreted proteins |
| 09/22/2005 | US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound |
| 09/22/2005 | US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response |
| 09/22/2005 | US20050208158 nutraceutic mixture comprising plant extract of steroid saponins and bio-active zinc, bio-active selenium; treating HIV, herpes virus; antiinflammatory agent treating veins, capillaries, kidneys, bladder, and prostate gland; increasing good cholesterol concentration; strengthening immune system |
| 09/22/2005 | US20050208154 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily |
| 09/22/2005 | US20050208127 Comprises D-mannitol having average particle diameter of 31-80 mu m, active ingredient, disintegrant, and stearic acid or metallic stearate in an amount of 0.01-0.5% by weight; rapidly disintegrates in oral cavity; method of external lubricating compression makes porosity small, enables small tablet |
| 09/22/2005 | US20050208124 Drugs containing riboflavin-type compounds |
| 09/22/2005 | US20050208065 Immunogenic compositions for induction of anti-tumor immunity |
| 09/22/2005 | US20050208064 Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide |
| 09/22/2005 | US20050208061 Treatment of autoimmune diseases by oral administration of autoantigens |
| 09/22/2005 | US20050208046 TWEAK receptor |
| 09/22/2005 | US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin |
| 09/22/2005 | US20050208035 Nutritional composition for treating an immune condition |
| 09/22/2005 | US20050208016 derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis, hiv |
| 09/22/2005 | US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid |
| 09/22/2005 | US20050207975 administering monoclonal Tac-antibodies; anticarcinogenic agents; immunotherapy |
| 09/22/2005 | DE10152351B4 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat Solid pharmaceutical formulation for a Piperazinharnstoffderivat |
| 09/22/2005 | CA2564614A1 Combinatorial interleukin-2 muteins |
| 09/22/2005 | CA2560200A1 Cd44-targeting for reducing/preventing ischemia-reperfusion-injury |
| 09/22/2005 | CA2559802A1 Method for stimulating the immune, inflammatory or neuroprotective response |
| 09/22/2005 | CA2558632A1 Improved interleukin-2 muteins |
| 09/21/2005 | EP1577391A1 Neutrokine alpha |
| 09/21/2005 | EP1577383A1 Novel adaptor protein binding to mammalian toll-like receptor 3 and gene thereof |
| 09/21/2005 | EP1577299A1 Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient |
| 09/21/2005 | EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use |
| 09/21/2005 | EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates |
| 09/21/2005 | EP1576964A1 Protease inhibitor |
| 09/21/2005 | EP1576954A1 Preferential inhibition of release of pro-inflammatory cytokines |
| 09/21/2005 | EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use |
| 09/21/2005 | EP1576100A2 Purified composition of bispecific molecules and methods of production |
| 09/21/2005 | EP1576090A2 Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences |
| 09/21/2005 | EP1576088A2 Dominant negative proteins and methods thereof |
| 09/21/2005 | EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 09/21/2005 | EP1576014A1 Antibodies against pd-1 and uses therefor |
| 09/21/2005 | EP1576011A2 Inhibition of il-17 production |
| 09/21/2005 | EP1575984A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| 09/21/2005 | EP1575973A2 Substitution derivatives of n sp 6 sp -benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds |
| 09/21/2005 | EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 09/21/2005 | EP1575926A1 New pyridazin-3(2h)-one derivatives |
| 09/21/2005 | EP1575672A2 Use of cd137 antagonists for the treatment of tumors |
| 09/21/2005 | EP1575617A1 Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis |
| 09/21/2005 | EP1575526A2 Dna vaccines encoding heat shock proteins |
| 09/21/2005 | EP1575521A2 Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof |
| 09/21/2005 | EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 09/21/2005 | EP1575480A2 Compositions and methods for the treatment of immune related diseases |
| 09/21/2005 | EP1534819A4 Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
| 09/21/2005 | EP1420790B1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 09/21/2005 | EP1377560B1 Piperazine derivatives as tachykinin antagonists |
| 09/21/2005 | EP1355641B1 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| 09/21/2005 | EP1339694B1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| 09/21/2005 | EP1294679B1 Beta-amino acid nitrile derivatives |
| 09/21/2005 | EP1265862B1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 09/21/2005 | EP1263446B1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/21/2005 | EP1140091B1 Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia |
| 09/21/2005 | EP1137640B1 Cyclic hydrazine derivatives as tnf-alpha inhibitors |
| 09/21/2005 | EP1087791B1 Inhibition of xenoreactive antibodies |